RenovoRx (NASDAQ:RNXT) vs. Annovis Bio (NYSE:ANVS) Head-To-Head Analysis

RenovoRx (NASDAQ:RNXT) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Profitability

This table compares RenovoRx and Annovis Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RenovoRx	N/A	-120.68%	-89.23%
Annovis Bio	N/A	-206.01%	-158.26%

Volatility & Risk

RenovoRx has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RenovoRx and Annovis Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1	0	2	0	2.33
Annovis Bio	1	2	3	0	2.33

RenovoRx currently has a consensus target price of $7.50, indicating a potential upside of 468.18%. Annovis Bio has a consensus target price of $17.33, indicating a potential upside of 682.54%. Given Annovis Bio’s higher probable upside, analysts plainly believe Annovis Bio is more favorable than RenovoRx.

Institutional & Insider Ownership

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares RenovoRx and Annovis Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$40,000.00	1,209.45	-$8.81 million	($0.38)	-3.47
Annovis Bio	N/A	N/A	-$24.59 million	($2.04)	-1.09

RenovoRx has higher revenue and earnings than Annovis Bio. RenovoRx is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Annovis Bio beats RenovoRx on 6 of the 11 factors compared between the two stocks.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.